KCM
CASC

Kennedy Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Kennedy Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-493,561
Closed -$1.83M – 796
2017
Q4 		$1.83M Buy
+493,561
New +$2.02M 0.03% 623

Kennedy Capital Management's CASC Position: Q1 2018 in Review

Kennedy Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 493,561 shares — an estimated $1.83M sold.

Kennedy Capital Management first reported a position in CASC in Q4 2017 and held it in 1 quarter. The position peaked at $1.83M in Q4 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

  • Kennedy Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Kennedy Capital Management sold 493,561 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $1.83M.
  • Kennedy Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
  • Kennedy Capital Management's Cascadian Therapeutics, Inc. position peaked at $1.83M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Kennedy Capital Management's 13F filing for Q1 2018, filed 14 May 2018.